Promising assessment of Biotron on UK investment site www.stockopedia.co.uk.
It quotes a one-page report from Edison Investment research, that says in part…
“Australia’s Biotron is undoubtedly the smallest and least well known of the quoted players in hepatitis C and, as such, could offer the most highly geared, if perhaps also most speculative, play on the current M&A theme.”
The report concludes: “ the company offers a highly-geared interesting play on the HCV M&A theme with the added bonus that its lead product has potential in HIV. Furthermore, this also seems to be almost completely ignored by the market.”
Hopefully, there are a few international speculators whose appetites have been whetted by the $11bn Pharmasset deal. It would only need one or two to push the SP up and guarantee the exercise of the oppies. This is exactly what may happen if the HepDART presentation delivers.
location/location/location, page-25
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $7.664K | 403.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1202498 | 5 |
View Market Depth
| Last trade - 13.42pm 27/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |